We are live on ! Find out more
AGN

Allergan plc
AGN

Delisted

AGN was delisted on the 8th of May, 2020.

921 hedge funds and large institutions have $48.3B invested in Allergan plc in 2019 Q3 according to their latest regulatory filings, with 84 funds opening new positions, 303 increasing their positions, 386 reducing their positions, and 129 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more funds holding in top 10

Funds holding in top 10: 5899 (+41)

6% more capital invested

Capital invested by funds: $45.4B → $48.3B (+$2.89B)

5% less funds holding

Funds holding: 970921 (-49)

22% less repeat investments, than reductions

Existing positions increased: 303 | Existing positions reduced: 386

35% less first-time investments, than exits

New positions opened: 84 | Existing positions closed: 129

53% less call options, than puts

Call options by funds: $895M | Put options by funds: $1.89B

Holders
921
Holders Change
-49
Holders Change %
-5.05%
% of All Funds
20.2%
Holding in Top 10
99
Holding in Top 10 Change
+41
Holding in Top 10 Change %
+70.69%
% of All Funds
2.17%
New
84
Increased
303
Reduced
386
Closed
129
Calls
$895M
Puts
$1.89B
Net Calls
-$999M
Net Calls Change
-$835M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$4.08B +$18.2M +111,949 +0.5%
BlackRock
2
BlackRock
New York
$3.46B +$122M +748,168 +4%
State Street
3
State Street
Massachusetts
$2.49B +$276M +1,696,205 +13%
CS
4
Credit Suisse
Switzerland
$1.3B +$1.02B +6,266,725 +426%
Franklin Resources
5
Franklin Resources
California
$1.24B +$183M +1,125,072 +18%
ClearBridge Investments
6
ClearBridge Investments
New York
$1.19B -$199M -1,224,136 -15%
LP
7
Longview Partners
Guernsey
$1.17B -$901K -5,530 -0.1%
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$1.07B +$977M +5,996,300 +1,597%
FCM
9
Farallon Capital Management
California
$1.05B +$853M +5,235,000 +524%
UBS Group
10
UBS Group
Switzerland
$954M -$240M -1,472,121 -21%
JP Morgan Chase
11
JP Morgan Chase
New York
$942M +$460M +2,824,464 +102%
Bank of America
12
Bank of America
North Carolina
$933M +$392M +2,406,934 +77%
Goldman Sachs
13
Goldman Sachs
New York
$915M +$547M +3,355,325 +161%
Citigroup
14
Citigroup
New York
$825M +$603M +3,698,798 +307%
DKCM
15
Davidson Kempner Capital Management
New York
$809M +$609M +3,739,715 +351%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$771M +$61.1M +375,095 +9%
Northern Trust
17
Northern Trust
Illinois
$686M +$16.7M +102,776 +3%
Norges Bank
18
Norges Bank
Norway
$673M -$6.66M -40,866 -1%
Renaissance Technologies
19
Renaissance Technologies
New York
$618M +$152M +930,202 +34%
TP
20
Third Point
New York
$606M +$587M +3,600,000 New
Barclays
21
Barclays
United Kingdom
$587M +$463M +2,840,168 +439%
T. Rowe Price Associates
22
T. Rowe Price Associates
Maryland
$533M +$60.1M +368,679 +13%
PC
23
Paulson & Co
New York
$493M +$111M +682,670 +30%
N
24
Nuveen
North Carolina
$489M -$32.1M -197,026 -6%
Artisan Partners
25
Artisan Partners
Wisconsin
$454M -$798M -4,899,089 -65%

AGN Hedge Fund Activity: Q3 2019 in Review

921 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Allergan plc (AGN) for Q3 2019, worth a combined $48.3B — up 6.4% from $45.4B a quarter earlier.

Sellers outnumbered buyers: 129 funds closed out of AGN and 84 opened new positions — a net loss of 45 holders — while 386 trimmed existing stakes and 303 added.

The largest buyer was Credit Suisse, adding an estimated $1.02B. The largest seller was Wellington Management Group, cutting an estimated $3.43B.

  • 921 institutional investors held Allergan plc (AGN) as of Q3 2019, down from 970 in Q2 2019.
  • Funds reported $48.3B of Allergan plc stock for Q3 2019, up 6.4% quarter-over-quarter.
  • 84 funds opened new Allergan plc positions in Q3 2019 and 129 closed out, a net change of -45 holders.
  • The largest Allergan plc buyer in Q3 2019 was Credit Suisse, an estimated $1.02B added.
  • The largest Allergan plc seller in Q3 2019 was Wellington Management Group, an estimated $3.43B sold.

Based on aggregated 13F filings for Q3 2019.